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Abstract
Background: This retrospective study evaluated the impact of disease progression and of specific sites of
metastasis on patient reported outcomes (PROs) that assess symptom burden and health related quality of life
(HRQoL) in women with metastatic breast cancer (mBC).
Methods: HER-2 negative mBC patients (n = 102) were enrolled from 7 U.S. community oncology practices.
Demographic, disease and treatment characteristics were abstracted from electronic medical records and linked to
archived Patient Care Monitor (PCM) assessments. The PCM is a self-report measure of symptom burden and
HRQoL administered as part of routine care in participating practices. Linear mixed models were used to examine
change in PCM scores over time.
Results: Mean age was 57 years, with 72% of patients Caucasian, and 25% African American. Median time from
mBC diagnosis to first disease progression was 8.8 months. Metastasis to bone (60%), lung (28%) and liver (26%)
predominated at initial metastatic diagnosis. Results showed that PCM items assessing fatigue, physical pain and
trouble sleeping were sensitive to either general effects of disease progression or to effects associated with specific
sites of metastasis. Progression of disease was also associated with modest but significant worsening of General
Physical Symptoms, Treatment Side Effects, Acute Distress and Impaired Performance index scores. In addition,
there were marked detrimental effects of liver metastasis on Treatment Side Effects, and of brain metastasis on
Acute Distress.
Conclusions: Disease progression has a detrimental impact on cancer-related symptoms. Delaying disease
progression may have a positive impact on patients’ HRQoL.
Introduction
Breast cancer is the most common cancer among
women in the United States (excluding skin cancer) and
the second leading cause of cancer death in women
(second to lung cancer)[1]. Although disease incidence
in women decreased between 1999 and 2005, the inci-
dence of advanced disease has remained stable[2].
Few women (6%) diagnosed with breast cancer are
initially diagnosed with distant metastases. Of those who
are, 27.1% are alive after 5 years,[3] a rate considerably
lower than the 5-year survival rate for women diagnosed
with regional (84%) or localized (98%) disease[4].
In addition to those with advanced disease at diagnosis,
approximately 30% of patients diagnosed with earlier
stage disease will eventually develop metastases[5].
Given the high incidence of breast cancer, these data
suggest that a substantial and growing number of
women diagnosed with advanced disease will experience
an extended period of survival.
Treatment of metastatic breast cancer (mBC) may be
associated with physical symptoms and emotional dis-
tress that adversely impact patients’ physical functioning,
psychological well-being, and social support systems–all
dimensions of quality of life. Studies have also suggested
that health related quality of life (HRQoL) is positively
associated with subsequent survival duration,[6] making
it an important consideration in treatment decisions.
While the relationship between HRQoL and survival is
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patients provided with accurate, relevant information
regarding potential treatment side effects, symptom bur-
den and HRQoL during treatment showed decreased
emotional distress and anxiety, and an enhanced ability
for self care, [7,8] clear benefits of understanding the
impact of treatment.
Although there is a significant body of literature eval-
uating HRQoL in women with breast cancer,[9,10]
much of this work has been focused on survivorship,
[11-13] women treated in adjuvant settings,[14-16] or in
women with recurrent disease[17-19]. HRQoL research
with mBC patients has occurred primarily in the clinical
trial setting,[20-22] has included multiple cancer types,
[23] and has focused on characterizing HRQoL at either
a single point in time or at a couple of fixed time points
[23,24]. Although these studies may examine HRQoL
within different lines of therapy,[21] they generally do
not assess the impact of disease progression itself, and
are constrained in their ability to characterize the trajec-
tory of HRQoL over time.
The primary goal of this research was to evaluate the
impact on HRQoL of disease progression in general,
and of specific sites of metastasis, in a HER-2 negative
mBC population. An additional goal was to identify
those symptoms most often reported as severe at base-
line in this population. We focused on HER-2 negative
patients because they comprise the bulk of women
with breast cancer and because we believe that the
HRQoL trajectory may be different in women with
HER-2 positive disease. We hypothesized that disease
progression would be associated with a decrease in
composite indicators of HRQoL and worsening of
symptom burden related to fatigue, pain, and other
high frequency symptoms. We also hypothesized that
metastasis to different organ systems would differen-
tially affect self reported patient reported outcomes
(PROs).
Methods
Patients and Setting
This was a retrospective chart review and database ana-
lysis conducted at seven geographically distributed com-
munity oncology practices in the United States. Patients
were eligible if they were female, at least 18 years of age,
had a confirmed diagnosis of stage IV breast cancer,
were HER-2 negative, had experienced at least one dis-
ease progression after diagnosis with mBC per physician
note, had at least 180 days of follow up post progres-
sion, and had completed at least one Patient Care Moni-
tor (PCM) assessment, described further below, in the
60 days both prior and subsequent to the first disease
progression.
Procedures
Potentially eligible patients were identified by commu-
nity oncology practices affiliated with ACORN Research,
and medical charts reviewed to determine final study
eligibility. Completed case report forms were submitted
via dedicated facsimile to the ACORN analysis center
and entered into a secure database. Institutional review
board approval was obtained from IntegReview in
Austin TX.
Study Measures
The primary endpoints for this study were indices of
symptom burden and HRQoL as collected by the PCM.
PCM, version 2.0, is an 86-item self-report measure that
asks patients to rate the severity of symptoms on an 11
point (0 to 10) Likert-type scale, where higher scores
reflect more severe symptoms. Patients are instructed to
rate items to describe “how bad the symptom has been
for you during the past week, including today.” The
i t e m sa r eg e n e r a l l yas i n g l ew o r do rs h o r tp h r a s e ,s u c h
as: “Fatigue, tiredness or weakness,” or “Rash” for
physical symptoms; “I am sad or depressed,” for psycho-
logical symptoms; and “I am generally able to function
normally” for Physical functioning.
The PCM is administered via touch screen tablet PC
as a routine part of care at participating community
oncology practices, and takes 10 - 12 minutes to com-
plete after the first administration. The PCM produces
standardized scores (T scores) for six screening scales:
General Physical Symptoms, Treatment Side Effects,
Despair and Depression, Acute Distress, Impaired
Ambulation, and Impaired Performance. The PCM has
been shown to be valid for assessing HRQoL in cancer
patients and has been used in a number of studies
[25-29]. Demographic, disease, and treatment variables
were also collected, and their impact on PCM items and
index scores was assessed. These variables are listed in
T a b l e s1a n d2a n dd e s c r i b e di nt h es t a t i s t i c a la n a l y s i s
section.
Statistical Methods
Descriptive statistics were generated for all study vari-
ables. Linear mixed models were employed to examine
change in PCM index scores over time, controlling for
individual, disease and treatment characteristics. Meth-
ods followed those described by Littell et al. and Cnaan
et al.[30,31] Interval since diagnosis (Interval) was
modeled as a random effect, using restricted maximum
likelihood estimation. The covariance matrix of random
effects was specified as unstructured in each model.
Each model examined whether PCM scores were
collected before or after disease progression (Progres-
sion), and also examined the proximity of PCM survey
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mity). Proximity was modeled as logarithmic, except
as noted, to reduce its redundancy with Interval.
Because they were fundamental to the questions under
study, each model included Interval and Progression
irrespective of statistical significance. Analyses also
examined interactions of Progression with Proximity
and Interval.
The models examined several other variables, and
retained these if significant or nearly so. These include
the effect of being on vs. off chemotherapy at the time
of a PCM assessment, and having vs. not having meta-
static disease at each of several key sites at the time of a
PCM assessment (bone, brain, liver, lung, and perito-
neum). Each model also examined several patient-level
variables: 1) age, 2) race, 3) body mass index (BMI), 4)
stage of disease at initial diagnosis, 5) baseline ECOG
performance status (PS; 0 - 1 or missing vs. 2 - 4).
Models also examined first-line treatment regimen,
coded in three groups as taxane-based chemotherapy vs.
non-taxane-based chemotherapy vs. hormone therapy
only or no treatment. First line treatment regimen was
included only if significant. As a result, the effect of
regimen is reported for some models but not others.
Finally, we also examined whether first-line treatment
regimen contained bevacizumab, and included this vari-
able where significant.
Results are summarized in Table 3 for all PCM end-
points, and presented graphically for two PCM index
scores. Note that although disease progression
occurred after different intervals for different patients
(a factor modeled within each analysis), it is shown at
the median interval of about 9 months in the figures.
In addition to the reporting of statistical significance
for effects within each model, effects were also
described relative to the minimal important difference
(MID) of the effects[32,33]–the smallest change in
HRQoL that is important to the patient. This value is
0.5 to 1 point for individual PCM items, and 1.5 to
3 points for PCM index scores[34].
Analyses were conducted with SPSS Version 15.0. All
statistical tests were interpreted at alpha = .05, two
tailed, and no adjustment was made for multiple
comparisons.
Table 1 Demographic and Treatment Characteristics (N =
102)
Variable N (%)
Age (Mean, SD, Median) 57.0 (13.5) 57
Ethnicity
Caucasian 73 (71.6%)
African American 26 (25.5%)
Other 2 (2.0%)
Unknown 1 (1.0%)
BMI (Mean, SD, Median) 29.0 (6.5) 28.0
Had Prior Breast Cancer Surgery 89 (87.3%)
Had Prior Radiation Therapy 73 (71.6%)
Had Prior Neoadjuvant Therapy 16 (15.7%)
Had Prior Adjuvant Therapy 63 (61.8%)
First Line Therapy
None Reported 4 (3.9%)
Hormonal Therapy Only 30 (29.4%)
Taxane Based Therapy 43 (42.0%)
Non-Taxane Based Therapy 25 (25.0%)
Had Toxicity Related Discontinuation 7 (6.9%)
Received Second Line Therapy 92 (90.1%)
Had Toxicity Related Discontinuation 6 (6.5%)
Table 2 Disease Characteristics (N = 102)
Variable N (%)
Stage at Diagnosis
Stage I 12 (11.8%)
Stage II 33 ( 32.4%)
Stage III 20 ( 19.6%)
Stage IV 26 (25.5%)
Unknown 11 (10.8%)
ER Positive 76 (74.5%)
PR Positive 55 (53.9%)
ECOG PS
< 2 34 (33.3%)
= 2 6 ( 5.9%)
> 2 3 (3.0%)
Unknown 59 ( 57.8%)
# Months from initial dx to metastasis
(Mean, SD)
37.9 (42.3)
# Months from metastasis to first
progression (Mean, SD)
a
13.9 (14.8)
Had second disease progression 78 (76.5%)
# Months from 1st to 2nd progression
(Mean, SD)
6.6 (5.4)
Deceased Per Medical Record 45 (44.1%)
Metastatic Sites At initial
Metastatic
Diagnosis
At First
progression
Bone 61 (59.8%) 67 (65.7%)
Brain 0 (0.0%) 2 (2.0%)
Liver 27 (26.5%) 34 (33.3%)
Lung 29 (28.4%) 36 (35.3%)
Peritoneum 6 (5.9%) 6 (5.9%)
Other 35 (34.3%) 44 (43.1%)
Comorbidities Present (N,%)
Hypertension 49 (48%)
CHF 2 (2.0%)
History of MI or Stroke 4 (3.9%)
Other CVD 26 (25.5%)
Diabetes 18 (17.6%)
aMedian time from metastases to disease progression = 8.8 months
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Sample Development
A total of 387 potentially eligible women with stage IV,
HER-2 negative disease and at least one disease progres-
sion post mBC diagnosis were identified. Of these, 136
(35.1%) were ineligible due to insufficient PCM data,
primarily because the PCM was not uniformly adminis-
tered at all clinics. Another 15% of patients were
excluded because of insufficient medical chart data, 8.3%
because they received follow-up care at a non-participat-
ing clinic, 3.1% because of inadequate follow-up (i.e.,
< 180 days) after disease progression and 12.1% for
other reasons. The remaining 102 patients were deemed
study eligible, and represent the final study sample.
Figure 1 depicts sample development graphically.
Demographic, Disease and Treatment Characteristics
The sample was largely Caucasian (71.6%) or African
American (25.5%) with a mean age of 57.0 (13.5) years. All
subjects were women with stage IV HER-2 negative breast
cancer. The median time from metastasis to first disease
p r o g r e s s i o nw a s8 . 8m o n t h s( r a n g e :1 . 1t o7 4 . 9m o n t h s ) .
Additional information regarding demographic, disease,
and treatment characteristics is reported in Tables 1 and 2.
Patient Care Monitor Assessment
There were 1698 valid PCM assessments available from
101 patients in the study (mean = 16.1 assessments per
patient, SD = 14.0). Data from one patient was excluded
due to incompleteness. Of the 1698 PCM surveys, 46.4%
were completed after the first disease progression,
and 81.8% were completed while patients were on
chemotherapy.
Baseline Symptom Severity
Baseline symptom severity was of interest as an indica-
tor of the symptom burden with which patients begin
chemotherapy, and of the specific symptoms that tend
to be a problem. Baseline was defined as the interval
between metastatic diagnosis and start of chemotherapy
for this assessment. Fifty-four baseline PCM observa-
tions were available from 39 patients. Item ratings were
dichotomized for assessment of baseline symptom
Table 3 Summary of Mixed Model Results for PCM Items and PCM Index Scores
Mixed Model Results
Endpoint Change over time since
Diagnosis
(Interval)
Change at Disease
Progression
(Progression)
Change with Proximity to
Progression
(Proximity)
Main or Interaction
Effects
involving Regimen
Group
a
PCM Items
Fatigue Improving (p = .02) Worsened (p = .004) No effect Progression: H = NT > T (p
= .052)
b
Pain No effect Worsened (p = .051) No effect No effect
Trouble Sleeping No effect No effect No effect Main effect: H = NT < T (p
= .001)
PCM Index Scores
General Physical
Symptoms
Improving (p < .001) Worsened (p < .001) Tended to worsen leading into
progression, with less
improvement
leading out (p = .088)
No effect
Treatment Side
Effects
Improving (p = .013) Worsened (p < .001) No main effect Proximity: H = NT < T (p =
.005)
[Taxane had worse scores
distal from progression]
Acute Distress Improving (p = .002);
improving faster
after progression
(p = .022)
Worsened (p = .002) No effect No effect
Despair and
Depression
No effect No effect No effect No effect
Impaired
Ambulation
No effect No effect No effect No effect
Impaired
Performance
Improving (p = .003) Worsened (p = .003) No effect Main effect: H < NT (p =
.005)
> T (p = .004)
aH = Hormone therapy or no therapy, NT = Non-taxane based regimen, T = Taxane based regimen. Main effect = main effect of Regimen group; Progression =
interaction of regimen group with Change at Progression; Proximity = interaction of regimen group with Change with Proximity to Progression.
bP values are for
specific contrasts involving regimen groups, with Taxane and Hormone only groups tested against the Non-taxane, which was the reference condition. P values
for overall regimen effects are reported in the text where significant.
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symptoms. Of particular interest for this study were
those PCM items that contribute to the General Physical
Symptoms and Treatment Side Effects index scores, and
that were severe at baseline in 10% or more of cases.
Items from these indices, and the frequency with which
they were rated as severe at baseline, included fatigue
(15.0%), physical pain (17.5%), and trouble sleeping
(31.3%).
Linear Mixed Models Analysis of PCM Items
Linear mixed models analysis of the fatigue, tiredness
and weakness PCM item showed a small but significant
effect of Interval (p = .02), with scores decreasing
(improving) by about 1/3 point per year. Though signifi-
cant, this effect falls below the MID (≥ 0.5 points) over
the course of one year. ECOG PS 2 - 4 was associated
with scores 1.7 points higher (worse) than PS 0 - 1 (p =
.035). There was also a significant interaction of first-
line treatment regimen with Progression, in which
patients in the taxane group showed almost no increase
in fatigue scores at progression (about 0.1 points),
whereas other patients saw scores increase 0.7 - 0.8
points at progression.
Linear mixed models analysis of the PCM pain item
showed that pain ratings were lower (better) by 0.6 points
during chemotherapy (p < .001). Pain scores remained
flat over time, but increased about 0.3 points at progres-
sion, an effect that approached statistical significance (p
= .051) but that was not clinically relevant. The presence
of bone metastasis was a significant predictor (p = .008),
with scores about 1 point higher with bone metastasis
present. This effect was superimposed on the more mod-
est effect of progression itself, and may underestimate
the combined effect of disease progression which involves
spread of disease to the bone.
PCM data for the trouble sleeping item showed no
effects of Interval or Progression. Results did show a sig-
nificant effect of race (p = .045), in which Caucasian
patients reported sleep scores 1.7 points lower (better)
than minority patients. There was also an effect of lung
metastasis (p = .025), with scores about 1.5 points
higher (worse) when lung metastasis was present. In
addition, there was a main effect of first-line treatment
regimen (p = .004), in which patients on taxane regi-
mens had scores on trouble sleeping that were more
than 3 points higher (worse) than those on non-taxane
regimens. Mixed model results for Fatigue, Pain, and
Trouble Sleeping are summarized in Table 3.
General Physical Symptoms
Linear mixed model analysis of the General Physical
Symptoms index score showed a significant effect of
Interval (p < .001), with scores improving by 1 point
every 4 months. As noted, the MID for PCM index
scores is between 1.5 and 3 points. This indicates that
the improvement seen over 6 months is a clinically rele-
vant effect. Scores worsened at Progression by 2.4 points
(p < .001), but there was also a near significant interac-
tion of Progression with Proximity (p = .088). As shown
in Figure 2, the nature of the interaction was that scores
increased by about 2 points at progression, and resumed
gradual improvement from the elevated level. ECOG PS
2 - 4 (vs. PS 0-1 or missing) was associated with an
increase of 7.4 points in symptom severity (p = .016; not
shown). Being on a bevacizumab containing regimen
was also significant (p = .025), and was associated with
a 5.9 point decrease in symptom severity (not shown).
Figure 1 Flow Diagram of Study Sample Development.
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Analysis of the Treatment Side Effects index scores
showed a significant effect of Interval (p = .013), with
index scores decreasing (improving) about 1.5 points over
a 9 month period. There was also a significant effect of
Progression (p < .001), with scores increasing 2.3 points at
progression. Patients with ECOG PS 2 - 4 had scores
nearly 7 points higher (worse) than patients with PS 0-1 or
missing (p = .002). Scores were nearly 2 points higher on
chemotherapy vs. off (p < .001). The scores of patients
who had brain or liver metastasis at the time of the survey
were 5.4 and 2.7 points higher, respectively, than scores of
patients without the specific metastasis (p = .02 and p =
.001, respectively). Although the effect of brain metastasis
is large, it should be noted that only 1 - 2% of PCM sur-
veys were collected from patients with brain disease, com-
pared with 27% from patients with liver metastasis.
Results also showed a significant interaction between
treatment regimen and Proximity (p < .001; with
Proximity modeled as linear). The interaction, shown in
Figure 3, shows scores for the taxane group were higher
early in first line treatment than for the other regimen
groups, and were stable rather than improving after
progression.
Psychological Symptom Measures
Results for analysis of Acute Distress showed a signifi-
cant effect of Interval (p = .002), with scores improving
by about 1 point every 4 months. The main effect of
Progression was significant, and reflected a 2.3 point
increase in scores at disease progression. Interval inter-
acted with Progression (p = .022), in that the rate of
improvement in scores increased very slightly after dis-
ease progression. The effect of chemotherapy was also
significant (p = .042), with scores just over 1 point
lower (better) when patients were on vs. off chemother-
apy. There was also a significant effect of brain metasta-
sis (p = .033), with scores about 8 points higher when
brain metastasis was present.
Linear mixed model analysis of Despair and Depres-
sion index scores showed almost no effects. Scores were
stable over time, and increased less than 1 point at dis-
ease progression–both nonsignificant effects. ECOG PS,
however, was significant (p = .021), with ECOG PS 2 - 4
associated with an increase of 5.8 points in symptom
severity.
Physical Functioning Measures
Linear mixed models analysis of Impaired Ambulation
index scores showed no significant effects of either
Interval or Progression. However, there was a significant
effect of ECOG PS (p = .001), with ECOG PS 2 - 4 asso-
ciated with an increase of 9.6 points in symptom sever-
ity compared with ECOG PS 0-1 or missing. There was
also a counterintuitive effect of lung metastasis (p =
.008), with scores 3.3 points lower (better) when lung
metastasis was present. The explanation for this effect is
unknown.
Analysis of Impaired Performance showed a signifi-
cant effect of Interval (p = .003), with scores improving
by about 1 point every 4 months. The effect of Pro-
gression was also significant (p = .003), with a 1.7
point increase in scores at progression. After progres-
sion, scores resumed the pattern of gradual improve-
m e n t .T h e r ew a sa l s oas i g n i f icant effect of treatment
regimen (p = .006), with patients on non-taxane based
therapies scoring nearly 7 points higher (worse) than
patients on other therapies. ECOG PS was again signif-
icant (p = .001), with ECOG PS 2 - 4 associated with
scores that were 12.1 points higher (worse) than
patients with ECOG 0-1 or missing. Mixed model
results for all of the PCM index scores are summarized
in Table 3.
Discussion
The results of this retrospective research suggest that
disease progression in patients with HER-2 negative
Figure 3 Linear Mixed Model of Treatment Side Effects Index
Scores.
Figure 2 Linear Mixed Model of General Physical Symptom
Index Scores.
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ing of General Physical Symptoms, Treatment Side
Effects, Acute Distress and Impaired Performance
scores. The effects were not significant for Despair and
Depression or for Impaired Ambulation. It is plausible
that controlling for sites of metastasis attenuated the
estimated effect of disease progression for outcomes in
which a specific site of metastasis (e.g. liver, brain) was
significant. Although the effects of disease progression
appear less pronounced than corresponding effects
observed in previous study of breast cancer patients in
the adjuvant breast cancer treatment setting,[28] most
were statistically significant and reflect clinically relevant
symptoms or adverse effects.
By following patients with mBC through two lines of
therapy, this study provides an understanding of the tra-
jectory of HRQoL over time, and quantifies the impact
of disease progression across different HRQoL domains.
Since the current study examined HRQoL with repeated
assessments collected as a routine part of clinical care in
a real-world, community oncology setting, findings may
be more generalizable to the larger population than a
single or limited domain studies conducted as part of a
clinical trial.
We hypothesized that there would be deleterious
effects of disease progression evident on both PCM
index scores and individual PCM symptoms. Such
effects were observed across many, though not all, of
the PCM indices and items examined in this study, and
are generally consistent with previous research[23].
The effects of disease progression that were statisti-
cally significant also appeared clinically relevant (i.e.,
≥ MID), though smaller than the effects of disease
recurrence observed among adjuvant cancer patients,
[28] and smaller than some other effects examined in
this study (particularly performance status). This atte-
nuated effect should not be surprising, in that progres-
sion in the metastatic setting may not represent the
same change of status as progression in the adjuvant
setting, in which a patient may have previously thought
herself cured.
In addition to general effects of disease progression,
there were significant deleterious effects of specific sites
of metastatic disease on the Treatment Side Effects and
the Acute Distress index scores, and on the trouble
sleeping PCM item. The mechanism by which specific
sites of metastasis affect the outcomes is not clear, but
likely varies across site of metastasis and HRQoL
domain.
Although not a primary focus of the study, we did
examine the effect of first line treatment regimen, par-
ticularly taxane vs. not-taxane based treatments. Tax-
ane treatment is associated with significant toxicities,
including peripheral neuropathy, and joint or muscle
pain[35]. Interference with other activities, including
increased sleep problems such as reported in a recent
Canadian study,[36] and as reported in this study, may
reflect secondary effects of these toxicities. As shown
in Figure 3, patients on taxane therapies in the first
line appear to report somewhat elevated treatment side
effects. The overall effect of treatment regimen was
nonsignificant, but the taxane group did appear to
have more severe symptoms early in the first line
treatment period. This pattern would appear to reflect
adaptation to treatment side effects over the course of
first line therapy. In contrast to this, patients on non-
taxane chemotherapy had significantly worse Impaired
Performance index scores. Heightened symptoms for
the non-taxane group were not observed for other
PCM endpoints, and may reflect selection of patients
with existing performance impairment into non-taxane
treatment regimens.
Findings from this study may be useful to clinicians
in several ways. First, results of this study affirm that
disease progression in mBC patients has broad
impacts, affecting patients across multiple domains of
HRQoL. Beyond this, however, it is important to note
that the magnitude of the effects of progression
tended to be modest. Although the overall clinical pic-
ture for mBC patients may be very serious, many of
these patients appear to have adapted to their medical
situation, and to be relatively nonreactive to adverse
clinical events. This was especially evident in the psy-
chological functioning domains, in which patients
experienced distress from which they rebounded after
progression, and in which the progression event
appeared to not even register in Despair and Depres-
sion index scores. Clinicians should also note that
patients with poor PS had poorer HRQoL. Although
this is not surprising, it should be noted that the effect
of ECOG PS represents the most consistent and pro-
nounced effect on PROs observed in this study, an
effect generally several times that of disease progres-
sion. This information may be useful to clinicians as
they weigh the tradeoffs between efficacy, toxicity,
patient status, and quality of life in their choices of
treatment of mBC.
There were several limitations to this study. First,
although data were collected from a number of geogra-
phically distributed oncology practices, the study used a
convenience sample that may differ in unknown ways
from the underlying population. Second, the study was
retrospective, and therefore limited by the availability of
existing data in the assessment of HRQoL. Third,
although the number of assessments available for analy-
sis was relatively large, the number of patients from
whom these were drawn was more modest. Finally, we
examined patients with metastatic breast cancer treated
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not generalize to patients with other diseases, with dis-
ease at other stages, and to patients treated in other
settings.
Conclusions
Despite these limitations, the clear conclusion of this
study is that progressive disease in HER-2 negative
women with metastatic breast cancer is associated with
clinically relevant worsening of symptoms across multi-
ple domains, and that symptom severity may partly
depend on the organ systems affected by metastatic dis-
ease. Although this study was not interventional, these
findings suggest that delaying disease progression may
have a beneficial effect on the health related quality of
life of patients with metastatic breast cancer.
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